Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 9/20 | 0.50 |
| ▸ | DRD5 | P21918 | 8/20 | 0.50 |
| ▸ | DRD2 | P14416 | 8/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.50 |
| ▸ | DRD3 | P35462 | 7/20 | 0.50 |
| ▸ | ESR1 | P03372 | 5/20 | 0.50 |
| ▸ | DRD4 | P21917 | 5/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5516095 | 0.84 | ESR2 (0.50) | DRD1DRD5DRD2ESR2DRD3 | |
| SCHEMBL20860821 | 0.80 | ALDH1A1 (0.61) | DRD1DRD5ESR2ESR1 | |
| SCHEMBL5530730 | 0.80 | ESR2 (0.47) | DRD1DRD5DRD2ESR2DRD3 | |
| SCHEMBL5512730 | 0.77 | MEN1 (0.56) | DRD1DRD5DRD2ESR2DRD3 | |
| SCHEMBL31016406 | 0.76 | ESR2 (0.40) | DRD1DRD5DRD2ESR2DRD3 | |
| SCHEMBL5515881 | 0.76 | HTR3E (0.56) | DRD1DRD5DRD2ESR2DRD3 | |
| SCHEMBL5512037 | 0.76 | MAPT (0.59) | ESR2ESR1 | |
| SCHEMBL18960451 | 0.75 | MEN1 (0.50) | DRD1DRD5DRD2ESR2DRD3 | |
| SCHEMBL798654 | 0.75 | PDGFRB (0.43) | DRD1DRD5DRD2ESR2DRD3 | |
| SCHEMBL23735862 | 0.74 | ALDH1A1 (0.59) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256201-B2 | Selective estrogen receptor-β ligands | ASTRAZENECA AB (SE) | 2007-08-14 | — | — | US | disclosed |
| US-20050101584-A1 | Selective estrogen receptor-beta ligands | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101584-A1 | Selective estrogen receptor-beta ligands | ESR2, ESRRA, ESRRB | DRD1 753/4885DRD5 719/4885DRD2 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.